Worth a Shot: New Preventive Options Available for Respiratory Syncytial Virus-Respiratory Syncytial Virus Test Page (Optional Printable)

Respiratory Syncytial Virus Test Page (Optional Printable)

Pdf Summary

The document appears to be a test related to Respiratory Syncytial Virus (RSV) for the American Association of Medical Assistants, offering Continuing Education Units (CEUs). This test must be completed and postmarked by March 1, 2025, although it can also be completed online for immediate feedback and updates. The test questions focus on distinguishing facts about RSV and its implications compared to other infections like influenza and COVID-19. <br /><br />RSV is largely noted as a mild infection that clears within approximately a week, although it can result in serious conditions like pneumonia for high-risk groups, including older adults and those with chronic illnesses. The public is generally less aware of RSV's dangers compared to influenza. The document states RSV hospitalizes more infants in the United States than any other illness. <br /><br />Key points include that RSV cases have become more frequent throughout the year since the COVID-19 pandemic began. Whereas the likelihood of severe RSV decreases with age, those eligible for immunization, like older adults, should receive the vaccine annually in late summer or early fall. However, unlike vaccines, monoclonal antibodies, which are laboratory-made proteins, attach to viruses to prevent infection in healthy cells. <br /><br />Additionally, any infant under two months with a fever should be assessed by a healthcare professional. Notably, it's critical for infants to receive antibody immunizations intramuscularly in their arms. The Centers for Disease Control and Prevention (CDC) recommends the RSV vaccine to individuals aged 65 and older.

Keywords

Respiratory Syncytial Virus

RSV

American Association of Medical Assistants

Continuing Education Units

CEUs

RSV vaccine

monoclonal antibodies

CDC

infants

pneumonia